Luteolin inhibits BCL-2 at IC50 ~16 μM and BCL-XL at ~20 μM — similar potency to quercetin for BCL-2 family inhibition. It also inhibits NF-κB and NLRP3, providing direct SASP suppression alongside its senolytic mechanism. Human bioavailability is low (~5%) from standard forms but is improved with fat co-administration.

Should I use luteolin instead of quercetin?

Quercetin has significantly more clinical senolytic evidence (D+Q trials) than luteolin. Luteolin may be used as a supplementary agent alongside quercetin or as a quercetin complement for anti-inflammatory purposes.

What dose of luteolin is needed for senolytic effects?

No established human senolytic dose exists. Based on BCL-2 IC50 values, doses of 500–1,000 mg/day would be needed to approach relevant plasma concentrations — above typical supplement doses.